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Abstract: Turmeric obtained from the rhizomes of Curcuma longa has been used in the prevention
and treatment of many diseases since the ancient times. Curcumin is the principal polyphenol
isolated from turmeric, which exhibits anti-inflammatory, antioxidant, antiapoptotic, antitumor,
and antimetastatic activities. The existing evidence indicates that curcumin can exert a wide
range of beneficial pleiotropic properties in the gastrointestinal tract, such as protection against
reflux esophagitis, Barrett’s esophagus, and gastric mucosal damage induced by nonsteroidal
anti-inflammatory drugs (NSAIDs) and necrotizing agents. The role of curcumin as an adjuvant
in the treatment of a Helicobacter pylori infection in experimental animals and humans has recently
been proposed. The evidence that this turmeric derivative inhibits the invasion and proliferation
of gastric cancer cells is encouraging and warrants further experimental and clinical studies with
newer formulations to support the inclusion of curcumin in cancer therapy regimens. This review
was designed to analyze the existing data from in vitro and in vivo animal and human studies in
order to highlight the mechanisms of therapeutic efficacy of curcumin in the protection and ulcer
healing of the upper gastrointestinal tract, with a major focus on addressing the protection of the
esophagus and stomach by this emerging compound.
Keywords: curcumin; reflux esophagitis; gastroprotection; gastric ulcer; Helicobacter pylori; gastric
cancer
1. Introduction
Curcumin, the natural phenolic active ingredient of turmeric (Curcuma longa) rhizome, has
been used in Asia as an herbal remedy for a variety of diseases [1]. Similar to chili, turmeric is
commonly used in Asian cuisine to add a yellow color, both as a flavor and as a preservative [2].
In addition to the use of curcumin as an anti-inflammatory in ancient times, it has also been used
to treat gastrointestinal (GI) diseases such as indigestion, flatulence, diarrhea, and even gastric and
duodenal ulcers [1–3]. Recently, great attention has been paid to the medical applications of curcumin
in the treatment of human diseases associated with oxidative stress and inflammation, including
different cancers [3]. Curcumin treatment has also led to the improvement of metabolic parameters
involving aging-associated diseases such as atherosclerosis, diabetes, cardiovascular disease, and
chronic kidney diseases [4,5]. Interestingly, some promising effects of curcumin have been observed
in the alleviation by this turmeric derivative of the chronic inflammatory conditions such as arthritis,
uveitis, and inflammatory bowel disease [6]. In some instances, curcumin has been found to aid in the
prevention and treatment of various cancers [7]. Recently, the anticarcinogenic activity of curcumin
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has been documented in the GI tract because this compound has proven to exert a therapeutic effect
on different human GI cancers such as esophageal, gastric, and small and large intestinal cancer [8,9].
This overview was aimed to document the beneficial and emerging effects of curcumin in the upper GI
tract, focusing on the mechanism of local, systemic, and molecular actions of this compound in the
esophagus and stomach.
2. Curcumin in the Protection of the Esophagus against Reflux Esophagitis, Barrett’s Esophagus,
and Esophageal Carcinoma
The esophagus, which carries food and liquid from the mouth to the stomach, undergoes
transient lower esophageal sphincter relaxation (TLESR), which is considered the main mechanism
of gastroesophageal reflux disease (GERD) [10]. Under physiological conditions, these TLESRs are
induced spontaneously without swallowing and allow for the “physiological” contact of gastric juice
containing hydrochloric acid (HCl) with the esophageal wall [10]. Interestingly, this acid reflux occurs at
a higher frequency during TLESR in patients with GERD than in healthy subjects [10,11]. Furthermore,
the anatomical abnormalities in the structure of the lower esophageal sphincter or its dysfunction can
result in more frequent or sometimes prolonged exposure of the esophageal mucosa to gastric acid,
resulting in esophageal damage due to reflux esophagitis. If this mucosal contact of epithelial cells
with acid or acid and bile (mixed reflux) is prolonged, GERD develops [12]. Thus, human esophageal
epithelial cells are a direct target and play a key role in esophageal inflammation in response to acidic
pH in the course of GERD development. Complications of GERD development include Barrett’s
esophagus with an increased risk for esophageal adenocarcinoma formation [13]. In a study designed
to mimic the acid exposure experienced by GERD patients, treatment with curcumin prevented the
expression of inflammatory cytokines in human esophageal tissue [14]. This anti-inflammatory effect
of curcumin has been confirmed by an in vitro study, testing the protective potential of curcumin in
esophageal epithelial cell lines exposed to exogenous acid [15]. That study examined the HET-1A cell
lines exposed to hydrochloric acid in relation to the role of PKC, MAPK, and NFκB signaling pathways
and the transcriptional regulation of IL-6 and IL-8 expression [15]. This HET-1A cell line appears to be
suitable for investigating the cellular action of putative esophageal metaplasia development, and both
acid and bile are considered potent carcinogenic factors in the mechanism of esophageal dysplasia and
adenocarcinoma formation [15–17]. The exposure of HET-1A cells to pH 4.5 induced the activity of
the transcription factor NF-κB while enhancing IL-6 and IL-8 secretion and their mRNA and protein
expression [15]. Among the kinases system tested in their study [17], particularly the MAPKs and
PKC (alpha and epsilon) activity were activated when HET-1A cells were exposed to acid. Curcumin
was equally potent as SN-50 (an NF-κB inhibitor), chelerythrine (a PKC inhibitor), and PD-098059
(a p44/42 MAPK inhibitor), yet all of them efficiently abolished the acid-induced mucosal expression
of IL-6 and IL-8 [17].
In in vivo studies, curcumin was compared with lansoprazole, the proton pump inhibitor (PPI)
commonly used as the recommended standard drug against GI-tract disorders including GERD [18,19].
In these reports, curcumin was shown to effectively prevent the esophageal mucosal damage induced
by acute reflux esophagitis [18,19]. Although curcumin was documented as less potent than the proton
pump inhibitor (PPI) lansoprazole in the inhibition of acid reflux esophagitis, it became superior to
lansoprazole in the inhibition of mixed acid-bile reflux-induced esophagitis. This protective mechanism
caused by curcumin in the esophagus has been attributed to the antioxidant nature of this turmeric
derivative [18,19].
Gastroesophageal reflux is a major mechanism responsible for Barrett’s metaplasia, which
develops from the cellular reprogramming of the esophageal squamous epithelium due to the reflux
of acidic or acidic-bile content to the esophagus [20]. The protection against oxidative stress and the
preservation of the antioxidative activity induced by esophageal protectants play an important role in
the strategy against the pathogenesis of acid-induced esophageal mucosa damage. Thus, the anti-reflux
therapy alternative to PPIs is widely expected. In line with this notion, the anti-inflammatory properties
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of curcumin and the relationship between bile-reflux and the expression of antioxidative enzymes
and the reactive oxygen metabolites (ROM) scavenging enzyme MnSOD have been investigated [21].
The molecular approach was to examine therapies effective in the preservation of both the expression of
the antioxidative enzyme MnSOD at the level of the protein and the enzymatic activity of MnSOD [21].
Curcumin applied in the form of oil exerted an esophagoprotective activity against acidic reflux injury
through its ability to maintain mitochondrial function, as documented by the preservation of both
the MnSOD expression and activity by this turmeric compound [21]. These authors concluded that
curcumin oil prevented the loss of MnSOD expression in the rat esophageal epithelium caused by
bile [21]. In addition, the treatment with curcumin oil prior to acid or bile salt exposure prevented
the loss of MnSOD activity in an esophageal HET-1A cell line. Notably, when cells were treated with
curcumin oil, the highest level of MnSOD enzyme activity was observed [19]. However, it is worth to
mention that besides curcumin, MnTBAP and other nutraceuticals including certain berry extracts also
offered the efficient preservation of MnSOD expression in HET-1A cells [21].
Curcumin may offer a benefit over the single pathway-targeted anticancer therapy, and this effect
could be due to its pleiotropic properties [20]. Figure 1 summarizes the pleiotropic effects of curcumin
resulting in the amelioration of inflammation and cell death, which protects the tissue against injury.
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Figure 1. A conclusive summary of the pleiotropic action of curcumin in the body system: Curcumin
exhibits anti-inflammatory, antioxidant, antiapoptotic, antitumor, and antimetastatic activities and
suppresses multiple signalling pathways responsible for inflammation, apoptosis, and cellular
death. Curcumin improves the growth of neurons and the functions of the brain in addition to
the downregulation of reactive oxygen species, oxidative stress, and proinflammatory factors (NF-κB
and cytokines).
Considerable evidence indicates that curcumin can efficiently prevent the acid- and bile-induced
NF-κB changes from the normal mRNA phenotype into the oncogenic phenotype of human
hypopharyngeal primary cells (HHPC) in culture [22]. Curcumin inhibited the bile acid-induced
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genes dependent on the NF-κB signalling pathway in this HHPC culture. This turmeric was capable in
selectively inhibiting Bcl-2 overexpression induced in HHPC exposed to bile at both acidic (pH 4.0)
and neutral (pH 7.0) environments [22]. This evidence clearly indicates that curcumin might be
superior over NF-κB inhibitors. Furthermore, its beneficial anti-inflammatory and anticarcinogenic
effects are independent of pH status and can be explained either by the promotion of cell apoptosis
or the inhibition of antiapoptotic pathway in these HHPC cells [22]. In another study, the efficacy
of curcumin in the prevention of bile acid-induced DNA damage using micronucleus assay was
investigated [23]. Moreover, these authors tested the effect of curcumin on NF-κB and NF-κB p65
activities in the curcumin-pretreated esophageal cell line (OE33) exposed to deoxycholic acid (DCA)
using real-time PCR of the extracted RNA. In their study, the bile-induced DNA damage and the
activation of NF-κB activity in vitro were completely abolished by curcumin [23]. An important part
of this translational study has been run in human subjects and dealt with the curcumin efficacy to treat
patients with Barrett’s esophagus [23]. These patients with Barrett’s esophagus took a daily dose of
500 mg of curcumin tablets for 7 days prior to endoscopy [23]. Interestingly, curcumin-supplemented
patients presented a slightly reduced expression of IL-8 as compared to the squamous control tissue
non-treated with curcumin. However, this treatment resulted in an almost doubled apoptotic frequency
compared to the non-supplemented control patients [23]. To reiterate, the data has clearly indicated that
curcumin exerted a beneficial effect against bile-driven deleterious effects on the mucosal esophageal
cells. Although curcumin was poorly delivered to the esophagus, the supplementation of patients
with Barrett’s esophagus with curcumin not only reduced NF-κB activity and inflammatory features in
esophagi but also increased apoptosis in the Barrett’s esophageal tissues. This confirms that apoptosis
could be one of the potentially important mechanisms of the curcumin-beneficial effect on squamous
esophageal mucosa.
3. Curcumin-Induced Gastric Protection against NSAID-Induced Gastric Damage: Experimental
and Clinical Evidence
It is well-known that the ingestion of NSAIDs is associated with the risk of GI adverse effects
including gastric micro bleeding, damage to the epithelial structure, cessation of GI blood flow,
decline in gastric mucus and alkaline secretion, and alteration in GI motility [24]. The mechanism of
NSAID-induced gastropathy involves an impairment of the gastric mucosal barrier mainly due to the
inhibition of endogenous prostaglandins (PGs), which are considered prototypes of the cytoprotective
agents with the ability to protect the gastric mucosa against a variety of topical and non-topical
ulcerogenes [25,26]. The therapy with NSAIDs which includes aspirin, the most popular and widely
used world-wide, and other drugs, such as indomethacin, diclofenac or naproxen, have especially
brought great attention towards their anti-inflammatory potential and efficacy to treat rheumatoid
arthritis [24–27]. The most common adverse effects of NSAIDs documented in experimental animals
and confirmed in humans include potent ulcerogenic activity and the enhancement of oxidative
stress [27–29]. Therefore, the reduction of oxidative stress may be an effective curative strategy for
preventing and treating NSAIDs-induced gastric mucosal complications, such as micro bleedings
and hemorrhagic lesions. The alternative therapy by phytochemicals such as supplementation by the
dietary phenolic compounds including curcumin, could exert antioxidant, anti-inflammatory, and
antibacterial benefits, thus preventing digestive diseases of upper GI tract including the ulcerogenic
activity of NSAIDs [30].
In rodents, the NSAID-induced gastric mucosal damage is mainly localized to the oxyntic mucosa
of the stomach’s corpus region. These lesions are recognized as bleeding erosions or lesions rather
than typical ulcers [28]. This is contrary to the situation in humans, where NSAID-induced gastric
ulceration occurs mainly in the gastric antrum [31]. For instance, naproxen is the most common
and frequent NSAID used in rheumatoid arthritis patients, and the naproxen-induced gastropathy
occurs mainly in the gastric antrum [31]. Using this experimental antral model of gastric ulcerations
in rats to mimic the human scenario of complication risk after naproxen ingestion, Kim et al. [32]
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have shown that the administration of naproxen caused the macro- and microscopic antral lesions
and increased the tissue lipid peroxidation levels. When curcumin was combined with naproxen,
the size of the gastric antral ulcers had diminished, followed by the restoration of the activity of
antioxidative enzymes SOD, catalase, and glutathione peroxidase (GPx), which are all recognized as
ROM scavengers in the gastric mucosa [32]. Notably, curcumin protection was accompanied by the
fall in the lipid peroxides, suggesting that the mechanism of curcumin-induced attenuation of gastric
mucosal injury caused by NSAIDs such as naproxen can involve the inhibition of lipid peroxidation
and activation of radical scavenging enzymes [32]. Thus, the data clearly indicates that curcumin
possesses protective anti-antral ulcer properties due to its capability to decrease the damage of antral
gastric mucosa. Therefore, the future clinical utility of curcumin may offer an attractive strategy and
an encouraging opportunity for curing gastric lesions induced by NSAIDs in humans.
Recent studies confirmed that curcumin is an effective antioxidant and anti-inflammatory
compound in the upper GI-tract and a scavenger of ROM and nitrogen metabolites [33]. There is
considerable evidence that curcumin, which is not associated with significant adverse effects, exhibits
a comparable anti-inflammatory efficacy with those presented by some derivatives of NSAIDs [33–35].
Nowadays, it seems obvious that the mechanism of curcumin-induced gastroprotection against
indomethacin injury depends on the curcumin-mediated downregulation of pro-inflammatory
mediator expression, the decline in free nitrogen radical generation in addition to the enhanced
resistance of mucosal epithelium due to the inhibition of apoptosis, and the increased cell proliferation
in the gastric mucosa [33]. Ganguly et al. [34] have shown that curcumin is similar to melatonin with
regards to its down regulatory action against the activity of metalloproteinase-2 (MMP-2) generated
by ROM in animal models of gastric damage and during the course of ulcer healing. In addition,
the suppression of MMP-2 activity by H2O2 in a dose- and time-dependent manner in vitro was
blocked by antioxidants including curcumin [34]. Curcumin, similarly to melatonin and omeprazole,
afforded gastroprotection in vivo against indomethacin-induced gastric damage by the suppression of
gastric mucosal biosynthesis and expression of MMP-2 [34]. Interestingly, they have proposed that
the protection of curcumin, melatonin, and the PPI omeprazole against H2O2-mediated inactivation
depends on the downregulation of MMP-2 and TIMP-2 expression and the upregulation of MT1-MMP
during the onset of indomethacin-induced ulceration [34].
Morsy et al. [35] have confirmed the protective efficacy of curcumin against the damaging activity
of indomethacin in the rat stomach. Indomethacin administered intraperitoneally at a dose of 30 mg/kg
produced gastric bleeding erosions, predominantly due to the profound inhibition of endogenous
PG in the gastric mucosa evoked by this agent [24,25]. The pretreatment with a single dose of
curcumin reduced the index of indomethacin-induced gastric lesions and the malondialdehyde (MDA)
concentration, which is considered the index of ROM-induced lipid peroxidation [35,36]. Along with
the attenuation of the indomethacin-induced gastric mucosal damage, the concomitant increase in
mucin content of gastric juice and the gastric mucosal nitric oxide (NO) levels in rats pretreated with
curcumin have been observed [36]. Furthermore, the treatment with curcumin raised the antioxidant
enzyme catalase and SOD activities and decreased the expression of pro-inflammatory stimuli such as
inducible nitric oxide synthase (iNOS) and NF-κB. Curcumin attenuated gastric acid secretory activity,
an important component implicated in the pathogenesis of gastrointestinal peptic ulcer disease, and
inhibited the activity of caspase-3. This finding suggests that the mechanism of this protection depends
on the strengthening of the mucosal barrier and the antioxidant and antiapoptotic activities of this
compound. Of note, this beneficial gastroprotective effect of curcumin against NSAIDs could be
attributed, at least in part, to the antisecretory activity of this turmeric compound [37]. Interestingly,
the addition of microelements such as zinc (Zn) to curcumin enhanced the gastroprotective and
ulcer healing activities compared with those exhibited by curcumin alone [37]. Such a complex of
Zn(II)-curcumin dose-dependently reduced the severity of the indomethacin-induced gastric damage,
as reflected by the lower gastric ulcer index in animals treated with this combination [37]. Using
rats with chronic preexisting gastric ulcers, Mei and coworkers concluded that the Zn(II)-curcumin
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complex efficiently enhanced the mucosal barrier defence activity by the attenuation of oxidative
stress and MMP-9-mediated inflammation to a greater extent than curcumin alone [38]. Indeed, the
treatment with curcumin raised SOD activity and GSH levels and markedly inhibited the MDA content
and the expression of MMP-9 in the ulcerated mucosa [38]. In another report, curcumin-mediated
gastric mucosal healing has been associated with the upregulation of genes for MMP-2, TGF-β, and
VEGF. These effects were considered essential for an angiogenic modulatory role of this turmeric as
documented by its stimulatory effect on the vascular sprout formation and collagen fiber restoration in
ulcerated tissues [39]. In nineteen-hour animal ulcer models, Tuorkey and Karolin [40] have shown
that the mechanism of anti-ulcer activity of curcumin depends upon the attenuating effect of this
compound on gastric acid hypersecretion, total peroxides, MPO activity, IL-6 levels, and apoptotic
incidence. This observation was in keeping with the earlier study by Mathattanadul et al., who
have also indicated that both curcumin and bisdemethoxycurcumin can inhibit the basal gastric acid
secretion in pylorus-ligated rat model and that this antisecretory effect can contribute to an acceleration
of the healing of chronic gastric ulcerations of the mucosa [19].
To date, only a few studies mentioned above have been conducted—in vitro and especially
in vivo—on the inhibitory properties of curcumin affecting gastric secretion. Kim et al. demonstrated
that the Curcuma longa extract protected the gastric mucosa against ulceration with an extent similar to
ranitidine and inhibited gastric acid secretion in rats with pylorus ligation procedure, thus preventing
gastric mucosa from gastric ulcerations [41]. Zinc(II)-curcumin complex A also shared similar
antisecretory properties because this combination of zinc and curcumin provided protection against
indomethacin injury, in part, by the inhibition of gastric acid secretion [42].
The question remains whether the bioavailability of NSAIDs is affected by curcumin or if turmeric
shows the genuine gastroprotective action in the stomach. Zazueta-Beltran et al. have demonstrated
that the concurrent administration of indomethacin and curcumin resulted in a significant reduction of
gastric damage when compared to indomethacin alone [43]. However, the bioavailability parameters
of indomethacin and the prodrug acemetacin co-administered with curcumin was not significantly
altered after the administration of either the active compound or the prodrug. This important
evidence indicates that curcumin exhibits a protective effect against indomethacin-induced gastric
damage without marked change in bioavailability or through the pharmacokinetics of NSAIDs such as
indomethacin [43].
4. Role of Curcumin in the Protection against Gastric Mucosal Injury Induced by Strong
Necrotizing Agents and Stress-Induced Gastric Mucosal Bleeding Erosions
Despite the proven multi-target, anti-inflammatory properties of curcumin, the potential
protective action of this turmeric derivative against the gastric mucosal damage induced by noxious
agents has not been extensively studied. As a consequence, the mediating factors and mechanisms
of the potential protective effects of curcumin in the stomach injured by necrotizing agents such as
ethanol are poorly understood. Despite ethanol being known as a strong gastric-damaging agent
causing mucosal injury due to its direct contact with the gastric mucosa, ethanol-induced gastropathy
constitutes a serious clinical entity in humans [44]. In the original report, Mei et al. [37] have
demonstrated that the oral administration of a complex of zinc and curcumin (zinc(II)-curcumin)
dose-dependently reduced the severity of ethanol-induced gastric lesions while suppressing the gastric
acid secretory activity as reflected by the H+/K+-ATPase activity comparable with that exhibited by
the PPI, lansoprazole. Furthermore, Zn(II)-curcumin significantly inhibited TNF-α and IL-6 mRNA
expression, increased the activity of SOD and GPx, and reduced MDA levels in gastric mucosa of rats
when compared to the respective controls. These findings suggest that the gastroprotective activity
of the Zn(II)-curcumin complex might be important for stimulating cell proliferation and adjusting
the pro-inflammatory cytokine-mediated oxidative damage caused by ethanol insult of the gastric
mucosa [37].
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Previous studies have demonstrated that endogenous NO and other gaseous molecules such as
H2S and CO can cooperate with PG and sensory nerve neuropeptides such as calcitonin gene-related
peptide (CGRP) in the mechanism of gastric mucosal integrity and gastroprotection [45,46]. The recent
study by Czekaj et al. revealed that some of these factors, such as PG and NO, may contribute
to the mechanism of curcumin-induced gastric protection against ethanol injury [47]. They have
demonstrated that curcumin given intragastrically provided a dose-dependent gastroprotection against
gastric lesions induced by ethanol while increasing both the GBF and the plasma gastrin levels [47].
Furthermore, they proposed that curcumin-induced protection may depend upon the reduced mRNA
expression of pro-inflammatory mediators HIF-1α and caudal type home box 2 (Cdx-2), both also
recognized as tumour markers in the gastric mucosa [47]. The evidence that curcumin enhanced the
gastric mucosal expression of antioxidative enzymes HO-1 and SOD2 indicated that the mechanism of
gastroprotection-induced by this turmeric compound involves the enhancement of the antioxidative
status of gastric mucosa challenged by ethanol [47]. Interestingly, the mechanism of curcumin-induced
protection against ethanol injury could also depend upon the endogenous bioavailability of PG
because nonselective and selective COX-1 and COX-2 inhibitors (indomethacin, rofecoxib, and SC-560)
reversed this protection and the accompanying rise in GBF evoked by this polyphenolic compound.
Furthermore, the concurrent treatment with the synthetic analogue of PGE2 combined with these
COX-1 and COX-2 inhibitors restored the protective and hyperaemic activities of curcumin against
ethanol damage [47]. This clearly indicates that PG can be an important downstream effector of
curcumin-evoked beneficial protective action in the stomach. NO, which is an important endogenous
mediator of gastroprotection and ulcer healing, could be involved in the mechanisms underlying the
gastroprotective activity of curcumin because the L-NNA-induced depletion of NO biosynthesis in the
gastric mucosa abolished the gastroprotective effects of curcumin. Moreover, this gastroprotective effect
was accompanied by a marked reduction in the GBF. The concurrent treatment with L-arginine together
with L-NNA not only restored the protective and hyperaemic activities of curcumin against ethanol
injury but also abrogated an increase in the mRNA expression of HIF-1α and Cdx-2 induced by L-NNA.
Nowadays it seems likely that CGRP released from sensory afferents as well as vanilloid receptor
TRPV1 can cooperate with PG and NO in the mechanism of the gastroprotective action of curcumin
against ethanol injury [48–51]. This notion is supported by the observation that the protection and
gastric hyperaemic response induced by curcumin were lost in animals with deactivated sensory nerves
by capsaicin and were further restored when exogenous CGRP was concurrently administered with
curcumin in rats with capsaicin-deactivated sensory nerves compromised by ethanol (Figure 2) [47].
Recent evidence indicates that curcumin can be effective as a protective substance against the
formation of stress-induced gastric lesions in rats [52], in part due to the inhibition of gastric secretory
activity mediated by a strong inhibitory action on H+/K +ATPase activity in parietal cells of the rat
stomach. Using a chromatin immunoprecipitation assay, He et al. have demonstrated that curcumin
inhibited the H+/K+ATPase promoter via histone acetylation, the gene and protein expression of the
gastric H+/K-ATPase α subunit, thus resulting in the rise in pH and the amelioration of stress-induced
gastric ulcerogenesis [52]. In another study, the anti-ulcer activity of curcumin in rats exposed to
either chronic stress and/or unpredictable stressors was observed simultaneously with an evident
improvement in memory deficit assessed in their study by the elevated plus maze test and by the
overall improvement of homeostatic functions [53]. The pretreatment of stressed rats with curcumin
via the oral route attenuated chronic stress and chronic unpredictable stress-associated memory deficits
and counteracted the increase in TBARS generation and the decrease in GSH content and markers
of oxidative stress (corticosterone, glucose, and creatine kinase) [53]. These authors concluded that
the curcumin-mediated antioxidant actions help the body to regulate corticosterone secretion and the
stress-induced ulcerative action and possibly to play an important central and peripheral adaptive role
against chronic and unpredictable stressors [53].
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The protective activity of curcumin against stress ulcerogenesis can involve the cooperation
of endoge ous prostaglandins and NO and the activity of capsaicin-sensitive fferent fibers
releasing CGRP and capsaicin receptors TRPV1 [54]. Recent studies revealed that the i tragastric
administration of curcumin dose-dependently prevented the formation of gastric bleeding erosions
in gastric mucosa compromised by cold stress. Furthermore, it inhibited basal an histamine- and
pentagastrin-stimulated gastric acid secretion, recognized as one of the major pathogenic factors
in str ss ulcerogenesis [54,55]. Interestingly, the gastroprotective effects of curcumin raised the
plasma concentration of gastrin in rats exposed to cold stress [55]. Gastrin is a hormone secreted
by the G cells of th APUD cells of the antral gastric muc sa known to exhibit a trophic effect on
mucosa, resulting in increasing cell proliferation and gastroprotection against the damaging effects of
ethanol and aspirin [56]. Exposure to stress increased th gastric mucosal expression of mRNA for
pro-infl mat ry markers TNF-α, COX-2, and iNOS, but these effects were inhibited by cur umi
administered in graded d sages [55]. The functional ablation of sensory affer nt nerves with capsaicin
or pretreatment with capsazepi e blunte the curcumin-in uced decrease in the lesi index and the
increase in GBF evoked by cold stress [55]. This vasoactive activity of curcumin corroborates the recent
Int. J. Mol. Sci. 2019, 20, 1477 9 of 14
observation that the turmeric derivative, as well as other curcuminoids, can exert vasodilatory activity
even in isolated organs [57]. These effects of curcumin in rats with capsaicin denervation were restored
by the concomitant treatment with exogenous CGRP combined with curcumin in rats subsequently
exposed to cold stress, therefore supporting the role of sensory afferent vasodilatory neuropeptides in
gastroprotection by this turmeric derivative against stress-induced gastric damage [55].
5. Efficacy of Curcumin to Treat the Impairment the Gastric Mucosa Infected by
Helicobacter pylori (H. pylori)
According to the World Health Organization (WHO), H. pylori has been accepted as a first-class
human pathogen implicated in the pathogenesis of major disorders of the upper GI-tract such as the
development of gastritis, peptic ulcers, MALT lymphoma, and in some cases, gastric adenocarcinoma.
The problem of an infection with H. pylori is nowadays important in the general population since
epidemiological studies have shown that over 50% of the populations is infected with H. pylori, with
a much higher rate in developing countries. Therefore, various drugs including antibiotics have
been routinely used for the eradication of this infection. However, steadily increasing resistance to
antibiotics, undesirable side effects, the raising costs, and the impaired H. pylori-infected patient’s
quality of life have given rise to the recent surge of interest in alternative approaches [58].
Recent evidence revealed that treatment with curcumin can attenuate oxidative stress and the
histological changes accompanying chronic gastritis associated with H. pylori. In a randomized clinical
trial, patients were divided into two groups: a standard triple therapy group and a group treated
with triple therapy with the concurrent administration of curcumin [58]. Endoscopic and histological
examinations were performed for all patients before and after 8 weeks of treatments [58]. Triple
therapy with curcumin adjuvant as a treatment group significantly decreased the MDA markers and
glutathione peroxides and increased the total antioxidant capacity of the gastric mucosa at the end
of study, compared to the baseline and triple regimen groups without curcumin [58]. In addition,
the oxidative damage to DNA was significantly decreased in triple therapy with the curcumin group
at the end of study, compared to the baseline and the triple therapy [58]. This important study has
documented that curcumin added to the triple therapy markedly attenuated the inflammation scores
(active, chronic, and endoscopic) of patients, compared to the baseline and triple therapy group without
combination with curcumin [58]. These authors have concluded that curcumin added to the triple
anti-H. pylori therapy considerably increased the eradication rate, which was superior as compared
to triple therapy alone [58]. Using an experimental mouse model, the effects of curcumin on lipid
peroxidation level, MPO and urease activity, number of colonized bacteria, levels of anti-H. pylori
antibodies, biofilm formation, IFN-γ, IL-4, and gastrin and somatostatin levels in serum have been
studied [59]. While all parameters were increased in H. pylori-infected mice, the treatment with
curcumin notably reduced the number of bacteria colonizing gastric mucosa and attenuated the activity
of lipid peroxide, MPO and urease strongly supporting the hypothesis that curcumin can reduce the
effects of H. pylori infection due to its potent antioxidizing properties. Curcumin also exhibited a potent
antimicrobial activity against H. pylori isolates in mice infected with this bacterium [59]. In contrast, the
level of anti-IgG antibodies and somatostatin was increased following curcumin treatment, suggesting
that this compound possessed immunomodulation properties resulting in the normalization of the
feedback inhibition of gastrin by somatostatin disturbed in H. pylori-infected gastric mucosa [59].
Both pro-inflammatory NF-κB and the motogenic response in H. pylori-infected epithelial cells were
inhibited by curcumin [60]. In recent trials, the addition of curcumin to triple therapy regimes
ameliorated the oxidative stress and histopathologic changes in chronic gastritis-associated H. pylori
infections [61–63]. All together, these studies suggest that curcumin can be a useful supplement to
improve the gastric mucosal protection against chronic inflammation and may prevent the carcinogenic
changes in patients with chronic gastritis associated with H. pylori (Figure 2).
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6. Conclusions and Future Perspectives
The poor water solubility, dissolution, and retention time of curcumin in the stomach limits its
practical usefulness in the treatment of peptic ulcer disease and neoplastic alterations including oral,
esophageal, and gastric cancers in humans [62–64]. However, the therapeutic effect of curcumin might
be exerted by its metabolites. For instance, Jamil et al. [57] have studied the spasmolytic, inotropic,
and chronotropic activity of major curcumin metabolite tetrahydrocurcumin and the nonenzymatic
curcumin hydrolysis products ferulic acid, feruloyl methane, and vanillin. They concluded that
demethoxycurcumin and bisdemethoxycurcumin showed more pronounced spasmolytic effects in
guinea pig ileum as well as vasodilation and negative inotropic activity in guinea pig arteries and
atria, respectively, than those exhibited by a parent curcumin. This evidence seems to indicate that
both curcuminoids derivatives can contribute to the observed pharmacological effects of the C. longa
extract [57]. Thus, future studies are required to prove if the enrichment of extracts of C. longa with
curcumin metabolites demethoxycurcumin and bisdemethoxycurcumin could potently enhance the
therapeutic efficacy of curcumin. Recently, Chen et al. (65) have shown that plasma curcumin was
below the detection limit of 0.1 ng/ml after oral curcumin administration in healthy volunteers;
instead, only the curcumin metabolite, curcumin glucuronide, has been detected as early as 30 min
after curcumin administration and achieved a maximal concentration within 2.7 hours. This suggests
a rapid metabolism of curcumin which form the glucuronide conjugate (65). More importantly
Chen et al. (65) have revealed that the gene expression of antioxidative genes NRF2, HO-1, and
NQO1 was increased and the epigenetic genes for histone deacetylases HDAC1, HADAC2, HADAC3,
and HADFAC4 have been suppressed by curcumin glucuronide. They concluded that despite the
absence of the parent curcumin in the blood/plasma, the antioxidant and epigenetic modulatory
effects of curcumin glucuronide can explain the potential overall health beneficial effect of this herbal
medicinal product [65]. Thus, it is reasonable to believe that most of the curcumin effects in vivo
may be due to local and direct effects rather than systemic effects of this turmeric compound after
absorption. This notion which is supported by the pharmacokinetics and pharmacodynamics of
curcumin regulating antioxidant and epigenetic gene expression in humans could be of interest for
basic researchers and clinicians.
However, a recent study with a controlled release therapy of curcumin to treat gastric ulcers by
novel raft forming systems incorporating curcumin-Eudragit® EPO solid dispersions has triggered
attention with a great hope to develop a curcumin carrier with improved solubility and the dissolution
of this compound and its prolonged gastric residence time [66]. Importantly, these authors have
demonstrated a curative effect of this curcumin raft on the acetic acid-induced chronic gastric ulcer in
rats. The curcumin raft forming formulations at the dose of 40 mg/kg administered once daily showed
a superior effect in terms of the acceleration of the ulcer healing, as compared with the standard
antisecretory therapy with the PPI lansoprazole (1 mg/kg, twice daily) and a curcumin suspension
(40 mg/kg, twice daily) [66]. These studies have indicated that this new raft-forming system containing
curcumin solid dispersions could serve as a promising carrier for the specific delivery of poorly soluble
lipophilic compounds, such as curcumin, to treat upper GI tract disorders in humans.
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